Dr. Reddy’s Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock’s future prospects, with ratings ranging from ‘Buy’ to ‘Sell’.
Kaynes shares plunge 43% from October peak. Is a tactical rebound on the cards or more pain ahead?
Kaynes has plunged 43.5% from its October peak, with Friday’s 12.5% drop marking the steepest single-day decline. Momentum indicators remain bearish, signaling a risk of
December 7, 2025